Search

Application forms

The deadline for the EHA Corporate Sponsor application is September 6, 2024, at 13:00 (CEST). Interested in becoming an EHA sponsor? Below you will find all the application forms for all the available EHA Sponsor Programs.

Read more

Sponsors

If you want to go fast, go alone. If you want to go far, go together. We aim for long-term relationships with our partners and sponsors.

Read more

EHA Guidelines by Topic

AL Amyloidosis
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines (2021)
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022)
Anemia
Recommendations regarding splenectomy in hereditary hemolytic anemias (2017)
Management of…

Read more

Other COVID-19 Resources

Safety of COVID-19 vaccines – April updates

ECDC and EMA issue advice on fourth doses of mRNA COVID-19 vaccines

EMA recommends authorisation of COVID-19 medicine Evusheld

EMA recommends authorisation of booster doses of Comirnaty from 12 years of age

EMA recommends approval of Spikevax…

Read more

Selected EMA news

February 2025New medicines recommended for approval
Dyrupeg (pegfilgrastim) – biosimilar
Treatment to shorten the duration of neutropenia and help prevent febrile neutropenia after cytotoxic chemotherapy

Eltrombopag Accord (eltrombopag) – generic
Treatment of primary immune thrombocytopenia and thrombocytopenia associated with chronic hepatitis C
New information on…

Read more

Social Media Learning

EHA presents our own microlearning in 4 formats, covering diagnosis, pathology, clinical schemas, and clinical cases within topics in the European Hematology Curriculum.

Read more

Guidelines for hematologists

For guidance regarding COVID-19, see FAQ by the EHA SWG on Infections

EHA creates clinical practice guidelines for diagnosis and treatment of hematologic diseases.

Read more

Publications

Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry
Aiello TF, Salmanton-Garcia J, Marchesi F, et al. Haematologica. 2024 Aug 1;109(8):2693-2700.

Read more